Institut Curie has supplied an undisclosed sum to its second immuno-oncology spinout, Honing Biosciences, which will focus on improved drug delivery mechanisms.
France-based immuno-oncology developer Honing Biosciences has officially spun out of research centre Institut Curie, which equipped the startup with an undisclosed amount of seed capital.
Honing Biosciences will advance a protein delivery mechanism mainly focused on reprogramming immune system cells from the chimeric antigen receptor (Car-T cells), so they can recognise and destroy cancerous bodies.
The spinout aims to overcome some of the problems that have stalled other Car-T approaches, such as toxicity when treating blood cancers and a lack of efficiency tackling solid tumours.
Honing Biosciences will seek to use a similar delivery mechanism to also fight other chronic diseases, and will continue to partner Institut Curie on research and development.
Honing Biosciences is the second immuno-oncology spinout from Insitut Curie and the first company to receive funding from the institution since it launched a new tech transfer policy in 2017.
The company’s founding…
